Abstracts tagged "Juvenile idiopathic arthritis"

Abstract Number: 0854 • ACR Convergence 2022
Outcome of Uveitis in Juvenile Idiopathic Arthritis and Spondyloarthritis Patients – a 5-year Follow up Study
Filipe Pinheiro¹, Mariana Leuzinger-Dias², Bruno Fernandes³, Diogo Fonseca⁴, Joana Vilaça⁵, Luís Figueira⁶ and Iva Brito⁷, ¹Rheumatology Department, Centro Hospitalar Universitário de São João, Porto, Portugal, ²Ophtalmology Department, Centro Hospitalar Universitário de São João, Porto, Portugal, ³Rheumatology Deparment, Centro Hospitalar e Universitário de São João, Porto, Portugal, ⁴Rheumatology Department, Centro Hospitalar de Vila Nova de Gaia / Espinho, Vila Nova de Gaia, Portugal, ⁵Paediatrics Department, Hospital de Braga, Braga, Portugal, ⁶Ophthalmology Department, Centro Hospitalar Universitário de São João, Porto, Portugal, ⁷Pediatric and Young Adult Rheumatology Unit, Centro Hospitalar Universitário de São João, Porto, Portugal
Background/Purpose: Uveitis is a frequent complication of juvenile idiopathic arthritis (JIA) and juvenile spondyloarthritis (jSpA), and diagnosis is often challenging. The importance of uveitis relates…
Abstract Number: 0876 • ACR Convergence 2022
Investigation of Predictive Factors for Active Disease Status Within 24 Months of Juvenile Idiopathic Arthritis Diagnosis
Erin Balay¹ and Susan Shenoi², ¹University of Washington, Seattle Children's Hospital, Seattle, WA, ²Seattle Children's Hospital and Research Center / University of Washington, Seattle, WA
Background/Purpose: Juvenile Idiopathic Arthritis (JIA) is the most common rheumatologic disease in children. JIA disease course and prognosis varies significantly between its seven categories, and…
Abstract Number: 2211 • ACR Convergence 2022
Identification of Plasma Metabolomic Biomarkers of Juvenile Idiopathic Arthritis
Amar Kumar¹, Joshua Tartarian², Valentina Shakhnovich³, Carl Langefeld⁴, Daniel Lovell⁵, Susan Thompson⁶, Mara Becker⁷ and Ryan Funk⁸, ¹University of Kansas, Kansas City, KS, ²University of Kansas Medical Center, Kansas City, KS, ³University of Missouri-Kansas City School of Medicine & Children’s Mercy Kansas City, Kansas City, MO, ⁴Wake Forest School of Medicine, Winston Salem, NC, ⁵Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁶Cincinnati Children's Hospital Medical Center/Univ of Cincinnati College of Medicine, Blue Ash, OH, ⁷Duke University Medical Center/Duke Clinical Research Institute, Durham, NC, ⁸University of Kansas, Leawood, KS
Background/Purpose: Identification of disease and therapeutic biomarkers remains a barrier to the early diagnosis of and initiation of effective therapy for juvenile idiopathic arthritis (JIA).…
Abstract Number: 0855 • ACR Convergence 2022
Change in Short Term Outcomes Following Tolerated Disease Activity Level for Individuals with Juvenile Idiopathic Arthritis in the Childhood Arthritis and Rheumatology Research Alliance Registry
Melissa Mannion¹, Fenglong Xie¹, Timothy Beukelman¹, Jeffrey Curtis² and , for the CARRA Registry Investigators³, ¹University of Alabama at Birmingham, Birmingham, AL, ²University of Alabama at Birmingham, Hoover, AL, ³CARRA, Washington, DC
Background/Purpose: Current recommendations suggest treatment escalation for juvenile idiopathic arthritis (JIA) until the disease activity target is reached, ideally inactive or low disease activity. Our…
Abstract Number: 0877 • ACR Convergence 2022
Neutrophils Extracellular Traps Formation May Serve as a Biomarker for Disease Activity in Oligoarticular Juvenile Idiopathic Arthritis
Merav Heshin-Bekenstein¹, Szilvia Baron², Grant Schulert³, Anna Shusterman⁴, Rachel Shukrun⁴, Yoav Binenbaum⁴ and Ronit Elhasid⁵, ¹Dana Dwek Children's Hospital, Tel Aviv Medical Center Israel, Binyamina, Israel, ²Pediatric Hemato-Oncology Research Laboratory, Tel Aviv Medical Center, Tel Aviv, Israel, ³Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁴Tel Aviv Medical Center, Tel Aviv, Israel, ⁵Dana Children's Hospital, Tel Aviv Medical Center, Tel Aviv, Israel
Background/Purpose: Juvenile idiopathic arthritis (JIA) is the most common chronic rheumatic disease in children, causing significant morbidity. Despite the dramatic improvement in treatment, many patients…
Abstract Number: 2213 • ACR Convergence 2022
Multi-omic Analysis of Macrophage Activation Syndrome Associated with sJIA Reveals a Potential Role of Type I Interferons in the Expansion of Cycling T Cells
Kailey Brodeur¹, Liang Chen¹, zhengping huang², Yan Du¹, Holly Wobma³, Maria Taylor⁴, Joyce Chang³, Megan Day-Lewis³, Fatma Dedeoglu³, Olha Halyabar³, Mindy Lo³, Jane W. Newburger⁵, Mary Beth F. Son³, Robert Sundel³, Peter Nigrovic³, lauren henderson³ and Pui Lee³, ¹Boston Children's Hospital, Boston, MA, ²Guangdong Second Provincial Hospital, Guangzhou, China, ³Division of Immunology, Boston Children's Hospital, Boston, MA, ⁴Division of Immunology, Boston Children's Hospital, Brighton, MA, ⁵Department of Cardiology, Boston Children's Hospital, Harvard Medical School, Boston, MA
Background/Purpose: Macrophage activation syndrome (MAS) is a complication of systemic juvenile idiopathic arthritis (sJIA) characterized by cytokine storm and overt immune cell activation. We aim…
Abstract Number: 0856 • ACR Convergence 2022
A Cross-Sectional Description of Physical Activity (PA) in Children with Juvenile Idiopathic Arthritis (JIA): The LEAP Study (Linking Exercise, Activity, and Pathophysiology in Canadian Children with Arthritis)
Lori Tucker¹, Jaime Guzman², Lamia Hayawi³, Nick Barrowman³, Heather Macdonald⁴, Kristin Houghton⁵, David Cabral⁶, Bianca Lang⁷, Dax Rumsey⁸, Elizabeth Stringer⁹, Shirley Tse¹⁰, Roberta Berard¹¹, Claire Leblanc¹², Tommy Gerschman¹³, Liane Heale¹⁴, Karen Watanabe-Duffy¹⁵, Sarah Campillo¹², Natalie Shiff¹⁶ and Ciaran Duffy¹⁷, ¹British Columbia Children's Hospital, Vancouver, BC, Canada, ²University of British Columbia and BC Children's Hospital, Vancouver, BC, Canada, ³Children's Hospital of Eastern Ontario Research Institute, Ottawa, ON, Canada, ⁴University of British Columbia, Vancouver, BC, Canada, ⁵University of British Columbia - Vancouver, Vancouver, BC, Canada, ⁶BC Children's Hospital and University of British Columbia, Vancouver, BC, Canada, ⁷Dalhousie University - Halifax, Halifax, NS, Canada, ⁸Stollery Children's Hospital, Edmonton, AB, Canada, ⁹IWK Hospital, Halifax, NS, Canada, ¹⁰Division of Rheumatology, The Hospital for Sick Children; Child Health Evaluative Services, SickKids Research Institute; Department of Paediatrics, University of Toronto, Toronto, ON, Canada, ¹¹London Health Sciences Centre, London, ON, Canada, ¹²McGill University, Montréal, QC, Canada, ¹³University of British Columbia - Vancouver, North Vancouver, BC, Canada, ¹⁴McMaster University, Oakville, ON, Canada, ¹⁵Children's Hospital of Eastern Ontario, Ottawa, ON, Canada, ¹⁶Janssen Scientific Affairs, LLC, Horsham, PA, USA/ Department of Community Health and Epidemiology, College of Medicine, University of Saskatchewan, Saskatoon, Canada, Philadelphia, PA, ¹⁷University of Ottawa, Ottawa, ON, Canada
Background/Purpose: Participation in physical activity (PA) is a concern of children with JIA , however, factors associated with PA in these children are incompletely understood. …
Abstract Number: 0878 • ACR Convergence 2022
A United States Nationwide Analysis of Total Knee Arthroplasty in Patients < 21 Years Old
John Gibbons¹, Cynthia A. Kahlenberg¹, Deanna Jannat-Khah, DrPH, MSPH¹, Alexander B. Christ², Susan Goodman¹, Peter Sculco¹, Mark Figgie¹ and Bella Mehta³, ¹Hospital for Special Surgery, New York, NY, ²Keck School of Medicine of USC, Los Angeles, CA, ³Hospital for Special Surgery, Weill Cornell Medicine, New York, NY
Background/Purpose: Total knee arthroplasty (TKA) is rarely performed in patients under 21 years old and may be performed in this population due to conditions such…
Abstract Number: PP08 • ACR Convergence 2022
Learning to Advocate for Myself and the Young Adult Community While Finding My Place as a Patient Partner at CARRA (Childhood Arthritis and Rheumatology Research Alliance)
Ela Chintagunta¹, Courtney Wells² and Kristine Carandang³, ¹Young Patients' Autoimmune Research & Empowerment Alliance, Chicago, IL, ²University of Wisconsin-River Falls; Young Patients' Autoimmune Research and Empowerment Alliance, St. Paul, MN, ³Young Patients' Autoimmune Research & Empowerment Alliance, San Diego, CA
Background/Purpose: I was diagnosed with Juvenile Idiopathic Arthritis at the age of 13 when I was experiencing joint swelling in my lower body and my…
Abstract Number: L20 • ACR Convergence 2021
Efficacy of Emapalumab, an Anti-IFNγ Antibody in Patients with Macrophage Activation Syndrome (MAS) Complicating Systemic Juvenile Idiopathic Arthritis (sJIA) Who Had Failed High-Dose Glucocorticoids (GCs)
Fabrizio De Benedetti¹, Alexei Grom², Paul Brogan³, Claudia Bracaglia¹, Manuela Pardeo¹, Giulia Marucci¹, Despina Eleftheriou³, Charalampia Papadopoulou³, Pierre Quartier⁴, Jordi Antón⁵, Rikke Frederiksen⁶, Veronica Asnaghi⁶ and Cristina De Min⁶, ¹Bambino Gesù Children's Hospital IRCCS, Rome, Italy, ²Cincinnati Children’s Hospital, Division of Rheumatology, Cincinnati, OH, ³UCL Institute of Child Health, and Great Ormond Street Hospital NHS Foundation Trust, London, United Kingdom, ⁴Université de Paris, IMAGINE Institute, RAISE reference centre, Pediatric Immuno-Hematology and Rheumatology Unit, Necker Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France, ⁵Hospital Sant Joan de Déu, Division of Pediatric Rheumatology, University of Barcelona, Barcelona, Spain, ⁶Swedish Orphan Biovitrum AG (Sobi), Basel, Switzerland
Background/Purpose: MAS is a life-threatening complication of rheumatic diseases, occurring most frequently in sJIA. The mainstay of MAS treatment is high dose GCs; however, GCs…
Abstract Number: 0253 • ACR Convergence 2021
Rheumatoid Factor Status as a Predictor of Disease Activity and Disability:An Analysis of the New CARRA Registry Polyarticular Juvenile Idiopathic Arthritis Cohort
Nayimisha Balmuri¹, William Soulsby², Victoria Cooley³, Linda Gerber⁴, Erica Lawson² and Karen Onel¹, ¹Hospital for Special Surgery, New York, NY, ²University of California San Francisco, San Francisco, CA, ³Weil Cornell Medicine, New York, NY, ⁴Weill Cornell Medicine, New York, NY
Background/Purpose: Children with rheumatoid factor (RF) positive polyarticular JIA (pJIA) are less likely to go into remission and more likely to develop erosive disease than…
Abstract Number: 0977 • ACR Convergence 2021
Enhancement of Patient and Clinician Partnerships in Juvenile Idiopathic Arthritis Management Using a Point-of-Care Dashboard: Development and Pilot Testing
Erica Lawson¹, Lisa Johnson², Jabeen Ahmad², Vincent Del Gaizo³, Brittany Donaldson⁴, Julie Eller⁵, Yukiko Kimura⁶, Cathy Knucken⁷, Tzielan Lee⁸, Corinne Pinter⁹, Doreen Tabussi¹⁰, Alysha Taxter¹¹ and Aricca Van Citters², ¹University of California San Francisco, San Francisco, CA, ²Dartmouth College, Lebanon, NH, ³Childhood Arthritis & Rheumatology Research Alliance (CARRA), Whitehouse Station, NJ, ⁴Wake Forest University School of Medicine Brenner Children's, Winston Salem, NC, ⁵Arthritis Foundation, Washington, DC, ⁶Hackensack University Medical Center, New York, NY, ⁷Patient Partner, Byram, NJ, ⁸Stanford University School of Medicine, Palo Alto, CA, ⁹Patient Partner, Sugar Land, TX, ¹⁰Hackensack University Medical Center, Upper Saddle River, NJ, ¹¹Wake Forest Baptist Medical Center, Winston-Salem, NC
Background/Purpose: Health outcomes improve when people living with chronic conditions partner with their clinicians to coproduce care based on their values, preferences, goals, and the…
Abstract Number: 0254 • ACR Convergence 2021
Patient and Disease-Level Factors Associated with Sustained Cessation of Medication for Disease Remission in Systemic Juvenile Idiopathic Arthritis
Elaine Flanagan¹, Rosemary Peterson², Susan Shenoi³, Helena Chang⁴, Kelly Wang⁴, Rebecca Trachtman⁴ and Karen Onel⁵, ¹Emory/CHOA, Atlanta, GA, ²Dell Children's Medical Center, Austin, TX, ³Seattle Children's Hospital, Seattle, WA, ⁴Icahn School of Medicine at Mount Sinai, New York, NY, ⁵Hospital for Special Surgery, New York, NY
Background/Purpose: The emergence of IL-1 and IL-6 inhibitors (biologics) for the treatment of systemic juvenile idiopathic arthritis (SJIA) has dramatically improved patient outcomes. With higher…
Abstract Number: 1008 • ACR Convergence 2021
Synovial Fluid IL-36γ in Patients with Enthesitis Related Arthritis (ERA) Correlates with Disease Activity and Leads to Production of IL-6 by Fibroblast Like Synoviocytes
Amita Aggarwal, Sanjukta Majumder and Shivika Guleria, Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow, India
Background/Purpose: IL-36 has been implicated in the pathogenesis of spondyloarthropathies (SpA) like psoriasis and IBD. Enthesitis related arthritis (ERA) category of juvenile idiopathic arthritis (JIA)…
Abstract Number: 0255 • ACR Convergence 2021
Identification of Tolerated Disease Activity Level for Individuals with Juvenile Idiopathic Arthritis in the Childhood Arthritis and Rheumatology Research Alliance Registry
Melissa Mannion¹, Fenglong Xie¹, Timothy Beukelman¹, Jeffrey Curtis² and , for the CARRA Registry Investigators³, ¹University of Alabama at Birmingham, Birmingham, AL, ²Division of Clinical Immunology and Rheumatology, Department of Medicine, Department of Epidemiology, University of Alabama at Birmingham, Birmingham, AL, ³CARRA, Durham, NC
Background/Purpose: Recent treat to target recommendations for the treatment of juvenile idiopathic arthritis (JIA) recommend frequent evaluation and treatment intensification until the disease activity target…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.